Agios is a biopharmaceutical company cultivating strong bonds with patient communities, healthcare professionals and partners to deliver therapies for rare diseases. Agios markets a first-in-class pyruvate kinase (PK) activator for treatment of hemolytic anemia in adults with PK deficiency in the US. Agios is advancing a clinical pipeline of investigational medicines with programs in α- and β thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. Visit agios.com.